1887

Abstract

Five neutralizing antigenic sites have been identified on the surface of serotype O foot-and-mouth disease virus (FMDV). A set of mAb neutralization-escape mutant viruses was used for the first time to evaluate the relative use of known binding sites by polyclonal antibodies from three target species: cattle, sheep and pigs. Antibodies to all five neutralizing antigenic sites were detected in all three species, with most antibodies directed against antigenic site 2, followed by antigenic site 1. In 76 % of cattle, 65 % of sheep and 58 % of pigs, most antibodies were directed against site 2. Antibodies specific to antigenic sites 3, 4 and 5 were found to be minor constituents in the sera of each of the target species. This implies that antigenic site 2 is a dominant neutralization immunogenic site in serotype O FMDV and may therefore be a good candidate for designing novel vaccines.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.037952-0
2012-03-01
2020-01-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/3/488.html?itemId=/content/journal/jgv/10.1099/vir.0.037952-0&mimeType=html&fmt=ahah

References

  1. Aggarwal N., Barnett P. V.. ( 2002;). Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species. . J Gen Virol 83:, 775–782.[PubMed]
    [Google Scholar]
  2. Aktas S., Samuel A. R.. ( 2000;). Identification of antigenic epitopes on the foot and mouth disease virus isolate O1/Manisa/Turkey/69 using monoclonal antibodies. . Rev Sci Tech 19:, 744–753.[PubMed]
    [Google Scholar]
  3. Barnett P. V., Samuel A. R., Pullen L., Ansell D., Butcher R. N., Parkhouse R. M. E.. ( 1998;). Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse. . J Gen Virol 79:, 1687–1697.[PubMed]
    [Google Scholar]
  4. Baxt B., Vakharia V., Moore D. M., Franke A. J., Morgan D. O.. ( 1989;). Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. . J Virol 63:, 2143–2151.[PubMed]
    [Google Scholar]
  5. Bittle J. L., Houghten R. A., Alexander H., Shinnick T. M., Sutcliffe J. G., Lerner R. A., Rowlands D. J., Brown F.. ( 1982;). Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. . Nature 298:, 30–33. [CrossRef][PubMed]
    [Google Scholar]
  6. Bolwell C., Clarke B. E., Parry N. R., Ouldridge E. J., Brown F., Rowlands D. J.. ( 1989;). Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies. . J Gen Virol 70:, 59–68. [CrossRef][PubMed]
    [Google Scholar]
  7. Crowther J. R., Rowe C. A., Butcher R.. ( 1993a;). Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus. . Epidemiol Infect 111:, 391–406. [CrossRef][PubMed]
    [Google Scholar]
  8. Crowther J. R., Farias S., Carpenter W. C., Samuel A. R.. ( 1993b;). Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. . J Gen Virol 74:, 1547–1553. [CrossRef][PubMed]
    [Google Scholar]
  9. DiMarchi R., Brooke G., Gale C., Cracknell V., Doel T., Mowat N.. ( 1986;). Protection of cattle against foot-and-mouth disease by a synthetic peptide. . Science 232:, 639–641. [CrossRef][PubMed]
    [Google Scholar]
  10. Dunn C. S., Samuel A. R., Pullen L. A., Anderson J.. ( 1998;). The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease. . Virology 247:, 51–61. [CrossRef][PubMed]
    [Google Scholar]
  11. Fowler V. L., Paton D. J., Rieder E., Barnett P. V.. ( 2008;). Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle. . Vaccine 26:, 1982–1989. [CrossRef][PubMed]
    [Google Scholar]
  12. Fowler V. L., Knowles N. J., Paton D. J., Barnett P. V.. ( 2010;). Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion. . Vaccine 28:, 3428–3434. [CrossRef][PubMed]
    [Google Scholar]
  13. Grazioli S., Fallacara F., Brocchi E.. ( 2003;). Mapping of neutralising sites on FMD virus type Asia 1 and relationships with sites described in other serotypes. . In Report of the Session of the Research Foot and Mouth Disease Group of the Standing Committee of the European Commision of Foot and Mouth Disease, pp. 277–287. Greece: Food and Agriculture Organization. http://www.fao.org/ag/againfo/commissions/docs/research_group/greece04/App44.pdf
  14. Grazioli S., Moretti S., Barbieri I., Crosatti M., Brocchi E.. ( 2006;). Use of monoclonal antibodies to identify and map new antigenic determinants involved in neutralisation on FMD viruses type SAT 1 and SAT 2. . In Report of the Session of the Research Foot and Mouth Disease Group of the Standing Committee of the European Commision of Foot and Mouth Disease, pp. 287–297. Paphos, Cyprus: Food and Agriculture Organization. http://www.fao.org/ag/againfo/commissions/docs/research_group/paphos/App43.pdf
  15. Herremans T., Reimerink J. H. J., Kimman T. G., van Der Avoort H. G., Koopmans M. P. G.. ( 2000;). Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure. . Clin Diagn Lab Immunol 7:, 40–44.[PubMed]
    [Google Scholar]
  16. Kitson J. D., McCahon D., Belsham G. J.. ( 1990;). Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. . Virology 179:, 26–34. [CrossRef][PubMed]
    [Google Scholar]
  17. Krebs O., Ahl R., Straub O. C., Marquardt O.. ( 1993;). Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum. . Vaccine 11:, 359–362. [CrossRef][PubMed]
    [Google Scholar]
  18. Mahapatra M., Seki C., Upadhyaya S., Barnett P. V., La Torre J., Paton D. J.. ( 2011;). Characterisation and epitope mapping of neutralising monoclonal antibodies to A24 Cruzeiro strain of FMDV. . Vet Microbiol 149:, 242–247. [CrossRef][PubMed]
    [Google Scholar]
  19. Mateu M. G., Martínez M. A., Capucci L., Andreu D., Giralt E., Sobrino F., Brocchi E., Domingo E.. ( 1990;). A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. . J Gen Virol 71:, 629–637. [CrossRef][PubMed]
    [Google Scholar]
  20. Mateu M. G., Camarero J. A., Giralt E., Andreu D., Domingo E.. ( 1995;). Direct evaluation of the immunodominance of a major antigenic site of foot-and-mouth disease virus in a natural host. . Virology 206:, 298–306. [CrossRef][PubMed]
    [Google Scholar]
  21. McCahon D., Crowther J. R., Belsham G. J., Kitson J. D. A., Duchesne M., Have P., Meloen R. H., Morgan D. O., De Simone F.. ( 1989;). Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. . J Gen Virol 70:, 639–645. [CrossRef][PubMed]
    [Google Scholar]
  22. McCullough K. C., Crowther J. R., Carpenter W. C., Brocchi E., Capucci L., De Simone F., Xie Q., McCahon D.. ( 1987;). Epitopes on foot-and-mouth disease virus particles. I. Topology. . Virology 157:, 516–525. [CrossRef][PubMed]
    [Google Scholar]
  23. McCullough K. C., De Simone F., Brocchi E., Capucci L., Crowther J. R., Kihm U.. ( 1992;). Protective immune response against foot-and-mouth disease. . J Virol 66:, 1835–1840.[PubMed]
    [Google Scholar]
  24. Pay T. W., Hingley P. J.. ( 1987;). Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. . Vaccine 5:, 60–64. [CrossRef][PubMed]
    [Google Scholar]
  25. Pfaff E., Mussgay M., Böhm H. O., Schulz G. E., Schaller H.. ( 1982;). Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. . EMBO J 1:, 869–874.[PubMed]
    [Google Scholar]
  26. Rezapkin G., Martin J., Chumakov K.. ( 2005;). Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. . Biologicals 33:, 29–39. [CrossRef][PubMed]
    [Google Scholar]
  27. Rezapkin G., Neverov A., Cherkasova E., Vidor E., Sarafanov A., Kouiavskaia D., Dragunsky E., Chumakov K.. ( 2010;). Repertoire of antibodies against type 1 poliovirus in human sera. . J Virol Methods 169:, 322–331. [CrossRef][PubMed]
    [Google Scholar]
  28. Rieder E., Baxt B., Lubroth J., Mason P. W.. ( 1994;). Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. . J Virol 68:, 7092–7098.[PubMed]
    [Google Scholar]
  29. Rodriguez L. L., Barrera J., Kramer E., Lubroth J., Brown F., Golde W. T.. ( 2003;). A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge. . Vaccine 21:, 3751–3756. [CrossRef][PubMed]
    [Google Scholar]
  30. Rweyemamu M. M.. ( 1984;). Antigenic variation in foot-and-mouth disease: studies based on the virus neutralization reaction. . J Biol Stand 13:, 323–337. [CrossRef][PubMed]
    [Google Scholar]
  31. Samuel A. R.. ( 1997;). Genetic and antigenic studies on foot-and-mouth disease virus type O. PhD thesis, University of Hertfordshire, UK.
  32. Taboga O., Tami C., Carrillo E., Núñez J. I., Rodríguez A., Saíz J. C., Blanco E., Valero M. L., Roig X.. & other authors ( 1997;). A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. . J Virol 71:, 2606–2614.[PubMed]
    [Google Scholar]
  33. Thomas A. A. M., Woortmeijer R. J., Puijk W., Barteling S. J.. ( 1988a;). Antigenic sites on foot-and-mouth disease virus type A10. . J Virol 62:, 2782–2789.[PubMed]
    [Google Scholar]
  34. Thomas A. A. M., Woortmeijer R. J., Barteling S. J., Meloen R. H.. ( 1988b;). Evidence for more than one important, neutralizing site on foot-and-mouth disease virus. Brief report. . Arch Virol 99:, 237–242. [CrossRef][PubMed]
    [Google Scholar]
  35. Wickham H.. ( 2009;). GGplot2: Elegant Graphics for Data Analysis (use R), , 2nd edn.. New York:: Springer-Verlag;.
    [Google Scholar]
  36. Xie Q. C., McCahon D., Crowther J. R., Belsham G. J., McCullough K. C.. ( 1987;). Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. . J Gen Virol 68:, 1637–1647. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.037952-0
Loading
/content/journal/jgv/10.1099/vir.0.037952-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error